The German peptide therapeutics market is anticipated to project a CAGR of 5.0%, during the forecast period. Germany is one of the key economies of the European region in terms of revenue generation and future opportunities for the market. The country is also supporting the growth of the market by investing in numerous projects related to peptide research. Peptide Research Laboratory, based in Germany, is one of the laboratories engaged in the rapid R&D of novel products. BIOSYNTAN is also majorly focused on the R&D activities regarding peptide therapeutics for the treatment of various disorders in the country.
Visit for Global Peptide Therapeutics Market Report at: https://www.omrglobal.com/industry-reports/peptide-therapeutics-market
The German peptide therapeutics market is segmented on the basis of route of administration and application. Based on the route of administration, the market is bifurcated into parenteral administration and oral administration. On the basis of application, the market is segmented into cancer, metabolic disorder (diabetes & obesity), gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others including chronic kidney diseases, osteoporosis, and autoimmune disorder. Among these applications, metabolic disorder dominates the market in Germany.
Furthermore, some of the global players in the market include Novo Nordisk A/S, AstraZeneca Plc, CordenPharma International GmbH, Bachem Holding AG, and Sanofi SA. These companies are using several strategies to expand market share and gain a competitive advantage over their competitors. The strategies include new product launches, mergers and acquisitions, partnerships, and collaborations.
For instance, in July 2020, CordenPharma expanded peptide manufacturing capacity in CordenPharma Colorado, its GMP API facility in Boulder, CO (US). The company announced this expansion of its solid-phase peptide manufacturing capacity in order to accommodate a large spike in the demand for peptide APIs and to continue an overall growth strategy.
Research Methodology
The market study of the German peptide therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include:
The report is intended for drug manufacturing companies, pharmaceutical companies, insulin manufacturers, diabetes management companies, government organizations, regulatory bodies, hospitals & pharmacies, research institutes, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
The Report Covers:
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Market Determinants
3.1. Motivators
3.2. Restraints
3.3. Opportunities
4. Market Segmentation
4.1. Germany Peptide Therapeutics Market by Route of Administration
4.1.1. Oral
4.1.2. Parenteral
4.2. Germany Peptide Therapeutics Market by Application
4.2.1. Cancer
4.2.2. Metabolic Disorder
4.2.3. Gastrointestinal Disorders
4.2.4. Central Nervous System Disorders
4.2.5. Respiratory Disorders
4.2.6. Others (Kidney Disorder and Autoimmune Disorder)
5. Company Profiles
5.1. AstraZeneca PLC
5.1.1. Overview
5.1.2. AstraZeneca Plc in Peptide Therapeutics Landscape
5.1.3. Recent Developments
5.2. Eli Lilly and Co.
5.3. F. Hoffmann-La Roche Ltd.
5.4. GlaxoSmithKline PLC
5.5. Novartis International AG
5.6. Novo Nordisk A/S
5.7. Sanofi SA
1. GERMANY PEPTIDE THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
2. GERMANY PEPTIDE THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
1. GERMANY PEPTIDE THERAPEUTICS MARKET SHARE BY ROUTE OF ADMINISTRATION, 2019 VS 2026 (%)
2. GERMANY PEPTIDE THERAPEUTICS MARKET SHARE BY APPLICATION, 2019 VS 2026 (%)
3. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)